Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00748566
Other study ID # A1281173
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date December 2008
Est. completion date May 2012

Study information

Verified date March 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.


Description:

The trial was terminated prematurely on May 24, 2012, due to changes in organizational strategy and resources. The decision to terminate the trial was not based on any safety or efficacy concerns.


Recruitment information / eligibility

Status Terminated
Enrollment 172
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Subject must present at least 2 of the following risk factors of MS at screening: Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated triglycerides (TGs): =1.7 mmol/L (=150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: = 5.6 mmol/L. - According to the clinical judgment of the investigator, the risk factors for MS have developed in close temporal relationship to starting an antipsychotic medication. - Substitution to a less metabolically disruptive antipsychotic medication is considered. Exclusion Criteria: - Subjects with contraindication(s) to the use of Ziprasidone according to Canadian prescribing information. - Subjects with a history of treatment resistance. - Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that may confound the evaluation of the study drug. - Body mass index = 40 at baseline.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ziprasidone HCL (oral)
Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.

Locations

Country Name City State
Canada Pfizer Investigational Site Bathurst New Brunswick
Canada Pfizer Investigational Site Burlington Ontario
Canada Pfizer Investigational Site Calgary Alberta
Canada Pfizer Investigational Site Calgary Alberta
Canada Pfizer Investigational Site Chatham Ontario
Canada Pfizer Investigational Site Halifax Nova Scotia
Canada Pfizer Investigational Site Kingston Ontario
Canada Pfizer Investigational Site London Ontario
Canada Pfizer Investigational Site Markham Ontario
Canada Pfizer Investigational Site Medicine Hat Alberta
Canada Pfizer Investigational Site Medicine Hat Alberta
Canada Pfizer Investigational Site Mississauga Ontario
Canada Pfizer Investigational Site Montreal Quebec
Canada Pfizer Investigational Site Montreal Quebec
Canada Pfizer Investigational Site Montreal Quebec
Canada Pfizer Investigational Site Ottawa Ontario
Canada Pfizer Investigational Site Penticton British Columbia
Canada Pfizer Investigational Site Red Deer Alberta
Canada Pfizer Investigational Site Saskatoon Saskatchewan
Canada Pfizer Investigational Site St. John's Newfoundland and Labrador
Canada Pfizer Investigational Site Sudbury Ontario
Canada Pfizer Investigational Site Sydney Nova Scotia
Canada Pfizer Investigational Site Sydney Nova Scotia
Canada Pfizer Investigational Site Toronto Ontario
Canada Pfizer Investigational Site Toronto Ontario
Canada Pfizer Investigational Site Verdun Quebec
Canada Pfizer Investigational Site Victoria British Columbia
Canada Pfizer Investigational Site Windsor Ontario
Canada Pfizer Investigational Site Winnipeg Manitoba
Canada Pfizer Investigational Site Winnipeg Manitoba
Canada Pfizer Investigational Site Winnipeg Manitoba
Canada Pfizer Investigational Site Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Achieving at Least 1 Risk Factor Reduction From Baseline for Metabolic Syndrome (MS) MS risks factors: elevated (el) waist, men:>=102 centimeters(cm), women:>=88 cm (Asian origin:>=90 cm in men, >=80 cm in women); el triglycerides: >=1.7 millimoles per liter (mmol/L) (>=150 milligram per deciliter [mg/dL]); reduced high-density lipoprotein cholesterol (HDL-C), men:<1.03 mmol/L (<40 mg/dL), women:<1.3 mmol/L (<50 mg/dL); el fasting glucose: >=5.6 mmol/L (>=100 mg/dL); el systolic/diastolic blood pressure (SBP/DBP): SBP>=130 millimeters of mercury (mmHg) and/or DBP>=85 mmHg. Responder=at least 1 less risk factor at endpoint (premature discontinuation or Week 52) than baseline. Endpoint (premature discontinuation or Week 52)
Secondary Mean Change From Baseline in the Number of Risk Factors of Metabolic Syndrome (MS) at Week 4, 12, 28 and 52 MS risks factors: elevated waist circumference: greater than or equal to (>=)102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): less than (<)1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg. Baseline, Week 4, 12, 28, 52
Secondary Percentage of Participants With Metabolic Syndrome (MS) According to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII), metabolic syndrome is defined as a condition that includes 3 or more of 5 characteristics: abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose. Baseline, Week 4, 12, 28, 52
Secondary Number of Participants With Change From Baseline in Metabolic Syndrome (MS) Risk Factors at Week 4, 12, 28 and 52 MS risks factors: elevated waist circumference: >=102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): <1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg. Week 4, 12, 28, 52
Secondary Percentage of Participants With Individual Risk Factors of Metabolic Syndrome (MS) MS risks factors: elevated waist circumference: >=102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): <1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg. Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Waist Circumference at Week 4, 12, 28 and 52 Waist circumference data is reported separately for male and female participants. Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 4, 12, 28 and 52 BP measurement is recorded as systolic BP (SBP, BP when heart is contracting; it is the maximum arterial pressure during contraction of left ventricle) and diastolic BP (DBP, BP when heart is relaxing; it is the minimum arterial pressure during relaxation and dilation of ventricles). Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Triglyceride and High Density Lipoprotein-Cholesterol (HDL-C) Levels at Week 4, 12, 28 and 52 Triglyceride data is reported for whole study population whereas HDL-C data is reported separately for male and female participants. Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Fasting Glucose Level at Week 4, 12, 28 and 52 Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in 10-year Cardiovascular Heart Disease (CHD) Risk According to Framingham Scoring System at Week 4, 12, 28 and 52 Framingham scoring system risk factors: age (risk points range: -9 to 16), cholesterol (risk points range: 0 to 13), HDL cholesterol (risk points range: -1 to 2), smoking (risk points range: 0 to 9), and systolic blood pressure (risk points range: 0 to 6); total risk points range <0 to >=25, higher score indicates higher CHD risk. The risk points are transformed to 10-year risk percentage for CHD which ranges from <1% to >=30%, where higher percent indicates greater risk for CHD. Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Total Cholesterol (TC) and Low Density Lipoprotein-Cholesterol (LDL-C) Levels at Week 4, 12, 28 and 52 Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Weight at Week 4,12, 28 and 52 Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Body Mass Index (BMI) at Week 4, 12, 28 and 52 Body mass index calculated as weight in kilograms (kg) divided by height in (meters) squared (m)^2 . Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Glycosylated Hemoglobin (HbA1c) Concentration at Week 4, 12, 28 and 52 HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Insulin Level at Week 4, 12, 28 and 52 Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in the Physical Activity Index Score at Week 28 and 52 Physical activity (exercise) score derived for each participant based on the frequency and intensity of physical activities: regular walking, recreational activity, cycling, and sporting activity. Six categories of total score: inactive (range: 0-2), occasional (range: 3-5), light (range: 6-8), moderate (range: 9-12), moderately vigorous (range: 13-20), and vigorous (>=21). Higher total score = higher frequency and intensity of physical activity. Baseline, Week 28, 52
Secondary Change From Baseline in QT Interval Corrected for Heart Rate (QTc) at Week 4, 12, 28 and 52 QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTc is the QT interval corrected for heart rate. Corrected QT interval using Fridericia's heart rate correction formula: QTcF = QT/RR^1/3, where RR=RR interval in seconds (60 divided by heart rate). Baseline, Week 4, 12, 28, 52
Secondary Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive and Negative Subscale Scores at Week 12, 28 and 52 Assesses positive and negative symptoms, general psychopathology specifically associated with schizophrenia. Scale consists of 30 items, each rated on scale from 1 (symptom not present) - 7 (symptoms extremely severe). Sum of 30 items is defined as PANSS total score, range:30-210. 7 items make up positive scale (delusions, conceptual disorganization, hallucinatory behavior); total range: 7-49. 7 items make up negative scale (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); total range: 7-49. For each subscale, total score: higher score=greater severity. Baseline, Week 12, 28, 52
Secondary Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 12, 28 and 52 CGI-S is a single-item, clinician-rated scale that assesses the global severity of the participants overall illness. CGI-S ratings range from 1 (normal, not at all ill) to 7 (among the most severely ill participants). Baseline, Week 12, 28, 52
Secondary Clinical Global Impression-Improvement (CGI-I) Scale Score CGI-I is a single-item, clinician-rated scale that assesses global improvement in the participants clinical state in response to study treatment, and as compared to their status at pre-treatment baseline. Possible CGI-I scores range from 1 to 7, where 1=very much improved, 4=no change and 7=very much worse. Endpoint (premature discontinuation or Week 52)
Secondary Change From Baseline in Drug-Attitude Inventory-30-Item Scale (DAI-30) Score at Week 28 and 52 DAI, a 30-item scale measuring subjective responses to medication (including acceptability and tolerability which aims to understand the factors influencing treatment adherence). Scale has 15 items (statements) scored as true and 15 items scored as false. An overall calculated score ranged from -15 to 15, where a positive score indicated a positive subjective response (compliant), a negative score indicated non-compliance. Baseline, Week 28, 52
Secondary Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) Score at Week 28 and 52 SOFAS: a 0-100 single score scale focusing exclusively on participant's level of social and occupational functioning; not directly influenced by overall severity of participant's psychological symptoms; higher score = higher level of functioning. Baseline, Week 28, 52
Secondary Change From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Index (EQ-I) Score at Week 28 and 52 EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Baseline, Week 28, 52
Secondary Changes From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Visual Analog Scale (VAS) Score at Week 28 and 52 EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state. Baseline, Week 28, 52
Secondary Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at Week 1, 2, 4, 8, 12, 20, 28, 36, 44 and 52 C-SSRS assessed whether participant experienced following: completed suicide(1), suicide attempt(2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior"). Baseline, Week 1, 2, 4, 8, 12, 20, 28, 36, 44 and 52
See also
  Status Clinical Trial Phase
Completed NCT01196858 - Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland N/A
Completed NCT00136760 - Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia Phase 2
Completed NCT03309475 - Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind) N/A
Not yet recruiting NCT01968161 - Investigator Initiated Study - Asenapine Early Psychosis Phase 4
Completed NCT00135772 - Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2 N/A
Completed NCT02308462 - Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents N/A
Completed NCT03133143 - Video Games Among People With Schizophrenia N/A
Completed NCT00309452 - Specialized Treatment Early in Psychosis (STEP) N/A
Not yet recruiting NCT02240173 - Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia Phase 1/Phase 2
Completed NCT00218218 - Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia Phase 2
Completed NCT02321943 - Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study N/A
Completed NCT02928965 - The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms Phase 2
Completed NCT02307396 - Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Phase 4
Recruiting NCT00791882 - Social Skills Training in Refractory Schizophrenia N/A
Completed NCT00363181 - Side Effects of Antipsychotic Medications
Completed NCT00137189 - Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation N/A